title: Tuberculosis screening before anti-hepatitis C virus therapy in prisons.
authors.forename: Sergio
authors.initials: S
authors.lastname: Babudieri
authors.forename: Andrea
authors.initials: A
authors.lastname: Soddu
authors.forename: Monica
authors.initials: M
authors.lastname: Murino
authors.forename: Paola
authors.initials: P
authors.lastname: Molicotti
authors.forename: Alberto A
authors.initials: AA
authors.lastname: Muredda
authors.forename: Giordano
authors.initials: G
authors.lastname: Madeddu
authors.forename: Alessandro G
authors.initials: AG
authors.lastname: Fois
authors.forename: Stefania
authors.initials: S
authors.lastname: Zanetti
authors.forename: Pietro
authors.initials: P
authors.lastname: Pirina
authors.forename: Maria Stella
authors.initials: MS
authors.lastname: Mura
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects* / Q000627:therapeutic use; D006526:Hepatitis C / Q000175:diagnosis* / Q000188:drug therapy; D006801:Humans; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008403:Mass Screening; D011092:Polyethylene Glycols / Q000009:adverse effects* / Q000627:therapeutic use; D011329:Prisoners; D011859:Radiography; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D012008:Recurrence; D012254:Ribavirin / Q000009:adverse effects* / Q000627:therapeutic use; D014397:Tuberculosis, Pulmonary / Q000000981:diagnostic imaging* / Q000517:prevention & control*
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a